ABCSG 50 / BRCA-P Summary
A randomized, double-blind, placebo-controlled, multi-center, international phase 3 study to determine the preventive effect of denosumab on breast cancer in women carrying a BRCA1 germline mutation.
| Start: | 07/2019 |
| Coordinating Investigator: | Singer, Christian; Vienna |
| Sample size: | 2.918 (international) |
| Design: (Click to enlarge) |
 |
Share on